NCT06238245 is a Phase 2 clinical trial of Cyclophosphamid in Graft-versus-host Disease, sponsored by Beijing 302 Hospital.

Who is sponsoring NCT06238245?

NCT06238245 is sponsored by Beijing 302 Hospital.

What drugs are being tested in NCT06238245?

Interventions in NCT06238245: Cyclophosphamid.

What condition does NCT06238245 study?

NCT06238245 studies Graft-versus-host Disease, Hematological Malignancies.

Is NCT06238245 still recruiting?

NCT06238245 is currently not yet recruiting. Last updated 20 February 2024.

Last reviewed 2024-02-20 · How we verify

NCT06238245

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combination of ATG-based Conditioning Regimen and PTCy for GVHD Prevention in Allo-HSCT After PD-1 Blockade

Not yet recruiting Phase 2 Last updated 20 February 2024

What this trial tests

Phase 2 trial testing Cyclophosphamid in Graft-versus-host Disease in 22 participants. Not yet recruiting.

Timeline

28 February 2024

Primary endpoint
30 December 2025

30 June 2026

Quick facts

Lead sponsor	Beijing 302 Hospital
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	22
Start date	28 February 2024
Primary completion	30 December 2025
Estimated completion	30 June 2026

Drugs / interventions tested

Cyclophosphamid — full drug profile →

Conditions studied

Graft-versus-host Disease — all drugs for Graft-versus-host Disease →
Hematological Malignancies — all drugs for Hematological Malignancies →

Sponsor

Beijing 302 Hospital

Who can join

18 and older, any sex, with Graft-versus-host Disease or Hematological Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to evaluate the efficacy and safety of anti-thymocyte globulin combined with PTCy (post-HSCT cyclophosphamide, PTCy) in preventing graft-versus-host disease (GVHD) in allo-HSCT patients after anti-PD-1(anti-programmed cell death protein 1) antibody treatment. In this study, patients with hematological malignancies who needed to receive allo-HSCT after PD-1 antibody treatment were selected as the research subjects. Fludarabine and Busulfan was used as the conditioning regimen, and the dose of ATG (anti-thymocyte globulin, ATG) combined with PTCy was used as the GVHD prevention regimen. The aim of this study is to reduce the incidence of Regimen-Related Toxicity and GVHD without affecting engraftment and relapse, thereby reducing non-relapse mortality and further improving the survival of patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Anti-PD-1 combined with hypomethylating agent and CAG regimen bridging to allogeneic hematopoietic stem cell transplantation: a novel strategy for relapsed/refractory acute myeloid leukemia.
Wang YX, Wang A, Su YF, Wang J, et al · · 2024 · cited 4× · PMID 39221255 · DOI 10.3389/fimmu.2024.1409302

Verify or expand the search:

Other trials of Cyclophosphamid

Trials testing the same drug.

NCT06532799 — TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer · Phase 1, PHASE2 · recruiting
NCT06532812 — TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer · Phase 1, PHASE2 · recruiting
NCT06108739 — ATG Plus Low-dose PT-Cy for GVHD Prevention · Phase 3 · terminated
NCT06047171 — Rescue of Nephrons With ALE.F02 (RENAL-F02) · Phase 2 · recruiting
NCT05990985 — The Efficacy and Safety of the RCMOP Sequential Therapy as a First-line Treatment for Patients With Intermediate-to-high · NA · not yet recruiting

Other recruiting trials for Graft-versus-host Disease

Currently open trials in the same condition.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT04014413 — Safety and Efficacy of Fecal Microbiota Transplantation · NA · recruiting

Other Beijing 302 Hospital trials

Trials by the same sponsor.

NCT07514832 — VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial · Phase 2 · recruiting
NCT07297173 — Phase 1 Study of Chemotherapy Plus HLA-mismatched GPBMC Infusion Bridging to Allo-HSCT for R/R Leukemia · Phase 1 · recruiting
NCT06556862 — Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor · Phase 2 · not yet recruiting
NCT07106658 — TEAS for Variceal Bleeding Endoscopy in Cirrhosis · NA · completed
NCT06926647 — A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06238245 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing 302 Hospital
Last refreshed: 20 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06238245.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing